Login to Your Account



No Pain (Drug), No Gain

Pain Therapeutics, Durect Drop 30%+ After Remoxy CRL

By Tom Wall


Monday, June 27, 2011
Pfizer Inc. partners Pain Therapeutics Inc. and Durect Corp. shared the pain of an FDA complete response letter (CRL) on Pfizer's resubmission of the new drug application (NDA) for Remoxy (oxycodone) extended-release capsules CII.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription